ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
Executive Summary
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.